Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
22,065 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05152147 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers(HERIZON-GEA-01) | active not recruiting | Phase 3 | 920 | Jazz PharmaceuticalsINDUSTRY | 33 | Sep 24, 2026 | clinicaltrials |
| NCT05215340 | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations(TROPION-Lung08) | active not recruiting | Phase 3 | 740 | Daiichi Sankyo |
| 28 |
| Sep 24, 2026 |
| clinicaltrials |
| NCT05444998 | Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer | completed | Phase 2 | 20 | Xijing HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05552976 | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)(SUCCESSOR-2) | active not recruiting | Phase 3 | 606 | Bristol-Myers SquibbINDUSTRY | 27 | Sep 24, 2026 | clinicaltrials |
| NCT05752136 | Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma | recruiting | Phase 3 | 108 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06018337 | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | active not recruiting | Phase 3 | 541 | DualityBio Inc.INDUSTRY | 17 | Sep 24, 2026 | clinicaltrials |
| NCT06136559 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | recruiting | Phase 3 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 24, 2026 | clinicaltrials |
| NCT06462222 | Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 45 | Guangzhou Medical UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06601504 | Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL | completed | Phase 2 | 61 | HutchmedINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06660654 | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | active not recruiting | Phase 2 | 335 | Daiichi SankyoINDUSTRY | 9 | Sep 24, 2026 | clinicaltrials |
| NCT06799286 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 | 10 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06801665 | FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis | recruiting | Phase 2 | 30 | Hua JiangOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06890598 | Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer(SUNRAY-02) | recruiting | Phase 3 | 700 | Eli Lilly and CompanyINDUSTRY | 29 | Sep 24, 2026 | clinicaltrials |
| NCT06901531 | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer(LUCERNA) | recruiting | Phase 3 | 500 | Astellas Pharma Global Development, Inc.INDUSTRY | 22 | Sep 24, 2026 | clinicaltrials |
| NCT07069712 | A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | recruiting | Phase 2 | 100 | AstraZenecaINDUSTRY | 11 | Sep 24, 2026 | clinicaltrials |
| NCT07404202 | A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients(Pan HER2) | recruiting | — | 2,100 | AstraZenecaINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07465289 | A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis(MyVisionXT) | recruiting | Phase 3 | 100 | UCB Biopharma SRLINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT07468071 | Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments(KontRASt-R) | recruiting | Phase 1 / Phase 2 | 40 | Novartis PharmaceuticalsINDUSTRY | 10 | Sep 24, 2026 | clinicaltrials |
| NCT07559929 | A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. | recruiting | Phase 1 / Phase 2 | 200 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07585266 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) | recruiting | Phase 3 | 800 | GlaxoSmithKlineINDUSTRY | 15 | Sep 24, 2026 | clinicaltrials |
| NCT07711184 | A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer | recruiting | Phase 1 | 320 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT07722754 | Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial(BOND-4) | recruiting | Phase 2 | 160 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07757906 | Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection | active not recruiting | N/A | 220 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07800507 | Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07824934 | HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 110 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07833202 | A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | not yet recruiting | Phase 3 | 416 | Shanghai Jeyou Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07838532 | Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC(AUMO-RWE) | completed | — | 637 | Xin LiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07839988 | De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid Leukemia(DESCML) | not yet recruiting | Phase 4 | 280 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07840092 | Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma | recruiting | — | 500 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02650401 | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options(STARTRK-NG) | active not recruiting | Phase 1 / Phase 2 | 69 | Hoffmann-La RocheINDUSTRY | 9 | Sep 23, 2026 | clinicaltrials |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT03367676 | 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)(SOBER) | terminated | Phase 2 | 78 | Ruijin HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03478488 | Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC(KN035-BTC) | completed | Phase 3 | 472 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03899155 | Pan Tumor Rollover Study | recruiting | Phase 2 | 1,500 | Bristol-Myers SquibbINDUSTRY | 38 | Sep 23, 2026 | clinicaltrials |
| NCT04400695 | A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | recruiting | Phase 3 | 366 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)(BRUIN-MCL-321) | active not recruiting | Phase 3 | 500 | Loxo Oncology, Inc.INDUSTRY | 24 | Sep 23, 2026 | clinicaltrials |
| NCT05144997 | Lorlatinib Continuation Study | active not recruiting | Phase 4 | 76 | PfizerINDUSTRY | 8 | Sep 23, 2026 | clinicaltrials |
| NCT05193721 | A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors | completed | Phase 1 | 25 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05290194 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05312840 | Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer | completed | Phase 2 | 20 | People's Hospital of QuzhouOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | recruiting | Phase 2 | 454 | AstraZenecaINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT06088004 | Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 218 | Suzhou Abogen Biosciences Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06175637 | Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs(PEDIA) | active not recruiting | — | 409 | AstraZenecaINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06357533 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations(TROPION-Lung10) | recruiting | Phase 3 | 675 | AstraZenecaINDUSTRY | 21 | Sep 23, 2026 | clinicaltrials |
| NCT06561386 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%(RELATIVITY1093) | recruiting | Phase 3 | 1,000 | Bristol-Myers SquibbINDUSTRY | 31 | Sep 23, 2026 | clinicaltrials |
| NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 25 | Sep 23, 2026 | clinicaltrials |
Data updated 6 days agoSource updated unknownsource: clinicaltrials